MDxHealth (NASDAQ:MDXH) Downgraded to Strong Sell Rating by Wall Street Zen

Posted by Geri Gentry on May 17th, 2026

Wall Street Zen lowered shares of MDxHealth (NASDAQ:MDXH – Free Report) from a hold rating to a strong sell rating in a report issued on Saturday morning.

Other equities analysts have also issued reports about the stock. William Blair lowered shares of MDxHealth from an “outperform” rating to a “market perform” rating in a report on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of MDxHealth in a report on Friday, March 27th. BTIG Research decreased their price objective on shares of MDxHealth from $7.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday. TD Cowen restated a “buy” rating and issued a $1.50 price objective (down from $7.00) on shares of MDxHealth in a report on Thursday. Finally, Lake Street Capital decreased their price objective on shares of MDxHealth from $9.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, MDxHealth currently has an average rating of “Moderate Buy” and an average price target of $4.63.

View Our Latest Analysis on MDXH

MDxHealth Stock Performance

MDXH stock opened at $0.89 on Friday. The firm has a market cap of $44.20 million, a PE ratio of -1.37 and a beta of 1.60. The firm’s 50 day moving average price is $2.42 and its 200-day moving average price is $3.23. MDxHealth has a one year low of $0.68 and a one year high of $5.33.

MDxHealth (NASDAQ:MDXH – Get Free Report) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The firm had revenue of $23.90 million for the quarter, compared to analysts’ expectations of $30.89 million. MDxHealth had a negative net margin of 29.90% and a negative return on equity of 1,078.01%. Equities research analysts predict that MDxHealth will post -0.41 EPS for the current fiscal year.

Institutional Investors Weigh In On MDxHealth

Large investors have recently modified their holdings of the company. Intesa Sanpaolo Wealth Management purchased a new stake in shares of MDxHealth in the 4th quarter valued at approximately $36,000. Lido Advisors LLC purchased a new stake in shares of MDxHealth in the 3rd quarter valued at approximately $48,000. GSA Capital Partners LLP purchased a new stake in shares of MDxHealth in the 3rd quarter valued at approximately $48,000. Squarepoint Ops LLC purchased a new stake in shares of MDxHealth in the 4th quarter valued at approximately $51,000. Finally, Jefferies Financial Group Inc. purchased a new stake in shares of MDxHealth in the 3rd quarter valued at approximately $53,000.

MDxHealth Company Profile

(Get Free Report)

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.